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Abstract 
Erlotinib, a substrate drug metabolized by the CYP3A4 enzyme, is an epidermal growth 
factor receptor tyrosine kinase inhibitor used to treat non-small cell lung cancer 
(NSCLC). Concomitant use of erlotinib and the antiepileptic drug phenytoin, an inducer 
of CYP3A4, may result in a drug-drug interaction accompanied by changes in the blood 
concentrations of both drugs. We determined the blood concentration of each drug to 
confirm the interaction between phenytoin and erlotinib in a case of NSCLC with brain 
metastases. The phenytoin blood concentration (8.2–10.0 µg/mL) gradually increased 
3-fold (to 24.2 µg/mL) 7 months after the start of erlotinib (150 mg/d) co-administration. 
The erlotinib blood concentration which was maintained at 0.15–0.37 µg/mL under 
phenytoin co-administration, increased 12-fold (to 1.77 µg/mL) after the stoppage of 
phenytoin co-administration. The present case revealed that blood phenytoin increased 
and blood erlotinib decreased subsequent to the interaction of the 2 drugs in the 
CYP3A4 metabolic enzyme system. 
 
Keywords: drug-drug interaction, erlotinib, phenytoin  
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1. Introduction 
Erlotinib, a substrate drug metabolized by the CYP3A4 enzyme, is an epidermal growth 
factor receptor tyrosine kinase inhibitor used to treat advanced or metastatic non-small 
cell lung cancer (NSCLC) [1-3]. Erlotinib was sometimes used concomitantly with the 
antiepileptic drugs phenytoin, carbamazepine, or valproic acid in NSCLC patients with 
convulsions due to brain metastases [4,5]. A case report on the interaction between 
erlotinib and phenytoin showed that blood phenytoin levels increased after the start of 
erlotinib co-administration [6]. This interaction may be due to the inhibitory effects of 
erlotinib on phenytoin metabolism in the CYP system [6]. However, whether change in 
blood erlotinib levels occurs in this drug–drug interaction remains unclear, although a 
change in erlotinib metabolism by CYP3A4 during co-administration of phenytoin, a 
strong CYP inducer, is speculated [6].  
In the present case report, we determined phenytoin and erlotinib blood concentrations 
to confirm the clinical impact of the interaction of these 2 drugs in an NSCLC patient 
with brain metastases. The study was approved by the ethics committee of Ibaraki 
Prefectural Central Hospital (approval no: 26-4; dated April 23, 2014), and informed 
consent was obtained from the patient. 
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2. Case report 
A 59-year-old woman was diagnosed as having adenocarcinoma of the left upper lung 
lobe in July 2010. She underwent surgery and received adjuvant chemotherapy of 
cisplatin plus docetaxel (4 cycles) and S-1 (17 cycles). Two years later, she presented 
with convulsive seizures due to brain metastases and was started on phenytoin 
administration (180 mg/d). She received craniotomy for tumor resection and gefitinib 
administration (250 mg/d) in November 2012. Three months later, a reduction in the 
dose of gefitinib to administration every other day was required because of liver 
dysfunction. Then, the brain metastases recurred, as did the convulsive seizures, which 
required levetiracetam administration in addition to phenytoin. Gefitinib was switched 
to erlotinib (150 mg/d) in October 2014 because of tumor progression.  
The phenytoin blood concentration, which was maintained at 8.2–10.0 µg/mL during 
gefitinib treatment, increased to 24.2 µg/mL 7 months after the switch to erlotinib (Fig. 
1). Phenytoin was stopped because of nystagmus, a phenytoin toxicity symptom due to 
high concentrations of the drug in blood. The erlotinib blood concentration was 
maintained at 0.15–0.37 µg/mL during the 7-month phenytoin co-administration. The 
erlotinib blood concentration gradually increased after phenytoin co-administration was 
stopped and reached 1.77 µg/mL under the unchanged daily dose of erlotinib (Fig. 1) and 
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liver and kidney functions. 
 
3. Discussion 
This is the first case report describing change in blood drug concentrations due to an 
interaction between phenytoin and erlotinib, in which the concentration of phenytoin 
increased and that of erlotinib decreased during concomitant use of the drugs for 
NSCLC with brain metastases. 
The change in phenytoin blood concentration, which was increased by erlotinib 
co-administration, is similar to that previously described by Grenader at al [6]. They 
reported that phenytoin concentrations increased 4-fold, from 5.9–7.2 µg/mL at baseline 
to 13.5–25.3 µg/mL, under erlotinib co-administration [6]. The present case showed a 
similar elevation of phenytoin concentration, from 8.2–10.0 µg/mL at baseline to 16.1–
24.2 µg/mL under erlotinib co-administration (Fig. 1). Both cases showed toxic 
symptoms of phenytoin—nystagmus, diplopia, and unsteady gait—when the blood 
concentration exceeded the therapeutic range of phenytoin, ie, 10–20 µg/mL. This 
elevation of phenytoin blood concentration may be caused by the inhibitory effects of 
erlotinib on metabolism or by excretion of phenytoin. 
Since erlotinib is metabolized by CYP3A4 [7], change in CYP3A4 activity, including that 
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induced by drug-drug interaction, may cause the change in erlotinib blood concentration. 
Systemic exposure to erlotinib was reported to be increased by 86% and decreased by 
69% when the CYP3A4 inhibitor, ketoconazole [8], and inducer, rifampicin [9], were 
co-administered, respectively. Phenytoin, an inducer of CYP3A4, is known to provide 
drug interactions with CYP3A4 substrates including chemotherapeutic agents [10]. The 
present case also confirmed a reduction in erlotinib concentration of 79% to 92% during 
phenytoin co-administration. The erlotinib concentration, which was as low as 0.15–
0.37 µg/mL under phenytoin co-administration increased approximately 12-fold (to 1.77 
µg/mL) after stoppage of phenytoin, which corresponded to the change in erlotinib 
clearance from 41.7 to 3.53 L/h. The erlotinib clearance under phenytoin 
co-administration (41.7 L/h) was extremely high (10-fold higher) when compared with 
previously reported values ranging from 4.14 to 5.43 L/h [11]. Thus, interaction between 
phenytoin and erlotinib may increase erlotinib clearance, resulting in reduction in 
erlotinib exposure in addition to increase in phenytoin exposure. 
Reduction in erlotinib exposure failed to inhibit the progression of brain metastases, 
which was confirmed by change in the tumor size as assessed by magnetic resonance 
imaging (data not shown). Erlotinib blood concentration under phenytoin 
co-administration was extremely low when compared with those of a phase II trial [11] 
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and seemed to be insufficient for treating brain metastases. The present case, therefore, 
showed rapid progression of the brain metastases despite the switch from gefitinib to 
erlotinib.  
When using concomitant phenytoin and erlotinib, physicians should pay attention to 
possible drug–drug interactions inducing unfavorable effects from both drugs—toxic 
symptoms in the case of phenytoin and insufficient antitumor effects in the case of 
erlotinib, though the combination is not contraindicated. Therapeutic drug monitoring 
for phenytoin and erlotinib is recommended to optimize the relevant dose amounts 
when patients require concomitant use of both drugs.  
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Figure legend 
Figure 1. Blood concentrations of phenytoin and erlotinib. 
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Figure 1 
 
 
